Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GALECTIN THERAPEUTICS INCGALT · Entity 5577 | Director | June 26, 2026 | June 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GALECTIN THERAPEUTICS INC
Report date June 26, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,500 |
Ending reported balance
After 2026-06-29 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-06-26 · Exercise / conversion · Acquired 7,732 · Balance 14,232 F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 Row 2 · 2026-06-26 · Sale · Disposed 7,732 · Balance 6,500 F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 F2: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Row 3 · 2026-06-29 · Exercise / conversion · Acquired 22,268 · Balance 28,768 F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 Row 4 · 2026-06-29 · Sale · Disposed 22,268 · Balance 6,500 F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 F4: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.12. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2035-01-23 | Direct | 52,268 |
Reported balance
After 2026-06-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-26 · Exercise / conversion · Disposed 7,732 · Balance 52,268 F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 F3: The options vested 100% on December 31, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2035-01-23 | Direct | 30,000 |
Reported balance
After 2026-06-29 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-29 · Exercise / conversion · Disposed 22,268 · Balance 30,000 F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 F3: The options vested 100% on December 31, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025
F2: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3: The options vested 100% on December 31, 2025.
F4: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.12. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 29, 2026 Filed Jun 30, 2026 23:24 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock Option (right to buy) · Derivative | 22,268 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001133416-26-000061 · form4.xml · derivative · entry 6 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 22,268 shares Expires 2035-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 F3 · derivative.exercise_date: The options vested 100% on December 31, 2025. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 23:24 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 22,268 | $5.04 | $112,230.72 |
DisclosureSEC source: 0001133416-26-000061 · form4.xml · nonDerivative · entry 4 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,500 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 F4 · price: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.12. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 23:24 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 22,268 | $1.23 | $27,389.64 |
DisclosureSEC source: 0001133416-26-000061 · form4.xml · nonDerivative · entry 3 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 23:24 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock Option (right to buy) · Derivative | 7,732 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001133416-26-000061 · form4.xml · derivative · entry 5 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,268 Underlying: Common Stock · 7,732 shares Expires 2035-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 F3 · derivative.exercise_date: The options vested 100% on December 31, 2025. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 23:24 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 7,732 | $5.00 | $38,660.00 |
DisclosureSEC source: 0001133416-26-000061 · form4.xml · nonDerivative · entry 2 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,500 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 F2 · price: The shares were sold in multiple transactions at prices ranging from $5.00 to $5.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 26, 2026 Filed Jun 30, 2026 23:24 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 7,732 | $1.23 | $9,510.36 |
DisclosureSEC source: 0001133416-26-000061 · form4.xml · nonDerivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29. 2025, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025 Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:46 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001133416-26-000028 · form4.xml · derivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-01-16 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2026. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:05 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001133416-25-000067 · form4.xml · derivative · entry 4 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2032-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F3 · derivative.exercise_date: The options vested 100% on December 31, 2022.. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:05 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 4,706 | $7.04 | $33,120.83 |
DisclosureSEC source: 0001133416-25-000067 · form4.xml · nonDerivative · entry 3 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,500 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F2 · price: The shares were sold in multiple transactions at prices ranging from $7.11 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:05 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 19,793 | $7.04 | $139,303.13 |
DisclosureSEC source: 0001133416-25-000067 · form4.xml · nonDerivative · entry 2 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,206 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F2 · price: The shares were sold in multiple transactions at prices ranging from $7.11 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:05 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 20,000 | $1.98 | $39,600.00 |
DisclosureSEC source: 0001133416-25-000067 · form4.xml · nonDerivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 21:22 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 8,417 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001133416-25-000064 · form4.xml · derivative · entry 6 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,417 shares Expires 2028-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F3 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2018 and September 30, 2018, and 50% on December 31, 2018. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 21:22 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 8,417 | $6.30 | $53,027.10 |
DisclosureSEC source: 0001133416-25-000064 · form4.xml · nonDerivative · entry 4 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,206 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F2 · price: The shares were sold in multiple transactions at prices ranging from $6.25 to $6.40. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 21:22 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stok | 8,417 | $4.16 | $35,014.72 |
DisclosureSEC source: 0001133416-25-000064 · form4.xml · nonDerivative · entry 3 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 21:22 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock Option (right to buy) · Derivative | 19,793 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001133416-25-000064 · form4.xml · derivative · entry 5 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,417 Underlying: Common Stock · 16,790 shares Expires 2028-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F3 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2018 and September 30, 2018, and 50% on December 31, 2018. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 21:22 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 19,793 | $6.27 | $124,181.28 |
DisclosureSEC source: 0001133416-25-000064 · form4.xml · nonDerivative · entry 2 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,206 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F2 · price: The shares were sold in multiple transactions at prices ranging from $6.25 to $6.40. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 21:22 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 19,793 | $4.16 | $82,338.88 |
DisclosureSEC source: 0001133416-25-000064 · form4.xml · nonDerivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. Read SEC document |
| December 09, 2025 Filed Dec 10, 2025 13:15 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock Option (right to buy) · Derivative | 16,790 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001133416-25-000061 · form4.xml · derivative · entry 22 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,210 Underlying: Common Stock · 16,790 shares Expires 2028-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F11 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2018 and September 30, 2018, and 50% on December 31, 2018. Read SEC document |
| December 09, 2025 Filed Dec 10, 2025 13:15 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 16,790 | $6.27 | $105,206.14 |
DisclosureSEC source: 0001133416-25-000061 · form4.xml · nonDerivative · entry 15 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,206 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F12 · price: The shares were sold in multiple transactions at prices ranging from $6.25 to $6.31. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 09, 2025 Filed Dec 10, 2025 13:15 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 16,790 | $4.16 | $69,846.40 |
DisclosureSEC source: 0001133416-25-000061 · form4.xml · nonDerivative · entry 14 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 13:15 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001133416-25-000061 · form4.xml · derivative · entry 21 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F6 · derivative.exercise_date: The options vested 100% on December 31, 2023. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 13:15 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001133416-25-000061 · form4.xml · derivative · entry 20 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2031-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F5 · derivative.exercise_date: The options vested 100% on December 31, 2024. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 13:15 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001133416-25-000061 · form4.xml · derivative · entry 19 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F5 · derivative.exercise_date: The options vested 100% on December 31, 2024. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 13:15 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001133416-25-000061 · form4.xml · derivative · entry 18 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Underlying: Common stock · 20,000 shares Expires 2032-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F4 · derivative.exercise_date: The options vested 100% on December 31, 2022. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 13:15 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001133416-25-000061 · form4.xml · derivative · entry 17 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F3 · derivative.exercise_date: The options vested 100% on December 31, 2021. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 13:15 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 35,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001133416-25-000061 · form4.xml · derivative · entry 16 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2031-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F2 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2021, December 31, 2021, June 30, 2022, and December 31, 2022. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 13:15 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 20,000 | $6.00 | $120,040.00 |
DisclosureSEC source: 0001133416-25-000061 · form4.xml · nonDerivative · entry 13 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,206 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F7 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.05. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 13:15 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 20,000 | $1.11 | $22,200.00 |
DisclosureSEC source: 0001133416-25-000061 · form4.xml · nonDerivative · entry 12 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 13:15 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 35,000 | $6.02 | $210,665.00 |
DisclosureSEC source: 0001133416-25-000061 · form4.xml · nonDerivative · entry 11 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,206 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F10 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.08. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 13:15 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 35,000 | $2.11 | $73,850.00 |
DisclosureSEC source: 0001133416-25-000061 · form4.xml · nonDerivative · entry 10 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 13:15 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 25,000 | $5.95 | $148,650.00 |
DisclosureSEC source: 0001133416-25-000061 · form4.xml · nonDerivative · entry 9 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,206 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F8 · price: The shares were sold in multiple transactions at prices ranging from $5.69 to $6.05. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 13:15 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 25,000 | $1.72 | $43,000.00 |
DisclosureSEC source: 0001133416-25-000061 · form4.xml · nonDerivative · entry 8 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 13:15 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon stock | 20,000 | $5.96 | $119,240.00 |
DisclosureSEC source: 0001133416-25-000061 · form4.xml · nonDerivative · entry 7 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,206 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F9 · price: The shares were sold in multiple transactions at prices ranging from $5.69 to $6.034. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 13:15 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon stock | 20,000 | $1.98 | $39,600.00 |
DisclosureSEC source: 0001133416-25-000061 · form4.xml · nonDerivative · entry 6 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 13:15 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 20,000 | $5.96 | $119,240.00 |
DisclosureSEC source: 0001133416-25-000061 · form4.xml · nonDerivative · entry 5 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,206 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F9 · price: The shares were sold in multiple transactions at prices ranging from $5.69 to $6.034. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 13:15 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 20,000 | $2.11 | $42,200.00 |
DisclosureSEC source: 0001133416-25-000061 · form4.xml · nonDerivative · entry 4 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 13:15 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 35,000 | $5.95 | $208,250.00 |
DisclosureSEC source: 0001133416-25-000061 · form4.xml · nonDerivative · entry 3 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,206 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F8 · price: The shares were sold in multiple transactions at prices ranging from $5.69 to $6.05. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 13:15 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 35,000 | $2.86 | $100,100.00 |
DisclosureSEC source: 0001133416-25-000061 · form4.xml · nonDerivative · entry 2 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 13:15 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 4,000 | $6.01 | $24,020.00 |
DisclosureSEC source: 0001133416-25-000061 · form4.xml · nonDerivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,206 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025. F7 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.05. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| January 23, 2025 Filed Jan 30, 2025 17:40 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001133416-25-000026 · form4.xml · derivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: comm Stock · 60,000 shares Expires 2035-01-23 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2025. Read SEC document |
| December 30, 2024 Filed Dec 31, 2024 12:45 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 6,500 | $1.16 | $7,540.00 |
DisclosureSEC source: 0001133416-24-000074 · form4.xml · nonDerivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,206 Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 21:50 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001133416-23-000030 · form4.xml · derivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-01-26 F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2023. Read SEC document |
| January 24, 2022 Filed Jan 25, 2022 21:52 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001133416-22-000037 · form4.xml · derivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-01-24 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2022. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 20:35 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 70,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0000899243-21-013811 · doc4.xml · derivative · entry 2 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2031-03-25 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F3 · derivative.exercise_date: Such options vest when (i) the Company has received the interim results of its NAVIGATE clinical trial and (ii) makes a public announcement that it has received the interim results. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 20:35 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0000899243-21-013811 · doc4.xml · derivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-03-25 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: Such options vest 100% on March 31, 2022. Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 22:56 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 70,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0000899243-20-001114 · doc4.xml · derivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2030-01-09 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest as follows: 25% on each of June 30, 2020, December 31, 2020, June 30, 2021, and December 31, 2021. Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 20:32 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 8,706 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001179022-19-000039 · edgar.xml · derivative · entry 2 Shlevin Harold H. · CIK 0001557082 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,294 Underlying: Common Stock · 8,706 shares Expires 2026-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options were originally issued on January 20, 2016 in a grant of 38,000 options which vested 25% upon grant and then approximately 792 options vested per month through January 2019. Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 20:32 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 8,706 | $1.37 | $11,927.22 |
DisclosureSEC source: 0001179022-19-000039 · edgar.xml · nonDerivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 22:16 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 70,000 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001179022-19-000009 · edgar.xml · derivative · entry 1 Shlevin Harold H. · CIK 0001557082 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-01-16 F1 · derivative.exercise_date: The options vest as follows: 25% on each of June 30, 2019, December 31, 2019, June 30, 2020, and December 31, 2020. Read SEC document |
| June 13, 2018 Filed Jun 14, 2018 20:32 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 25,544 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001179022-18-000051 · edgar.xml · derivative · entry 4 Shlevin Harold H. · CIK 0001557082 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,456 Underlying: Common Stock · 25,544 shares Expires 2025-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018. F2 · derivative.exercise_date: The options vested as follows: 25% on January 29, 2015, the grant date, with the remainder vesting ratably on a monthly basis over a three year period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.